Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Conditions: Hemophilia B Interventions: Genetic: ANB-002, dose 1; Genetic: ANB-002, dose 2 Sponsors: Biocad Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials